menuBe part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Project Oncology®

Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma

8 chapters
Play All
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post SurveySkip straight to the post survey if you have already participated in this activity
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments

  • Overview

    Release date: 7/18/2024
    Expiration date: 7/18/2025
    Estimated time to complete: 1.0 hour

    This activity is not accredited for CME/CE credit.

    This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.

  • Provider(s)/Educational Partner(s)

    Jointly provided by:

  • Commercial Support

    Support for this activity has been provided through educational grants from Johnson & Johnson and Pfizer, Inc.

  • Target Audience

    This activity has been designed to meet the educational needs of community hematologist-oncologists and other health care providers involved in the care of RRMM patients.

  • Learning Objectives

    After completing this activity, participants should be better able to:

    • Evaluate recent clinical advances in the use of bispecific antibody therapy in patients with RRMM and their implications for clinical practice
    • Summarize the toxicity profiles of bispecific antibodies used in the treatment of RRMM, particularly with respect to CRS, neurotoxicity, and infections
    • Employ the recommended strategies to monitor for treatment complications and manage AEs associated with bispecific antibody therapy

  • Unapproved Product Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, and Pfizer do not recommend the use of any agent outside the labeled indications.

  • Disclaimer

    The information presented in this activity is for medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, or Pfizer. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Contact Information

  • Privacy

    This content is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. The information you provide on this site may be used to contact you about other relevant educational activities. RedMedEd will not knowingly share any personally identifiable information. For more information, contact education@redmeded.com.

  • Copyright

    © 2024. This program is held as copyrighted by the Multiple Myeloma Research Foundation and RedMedEd. Through this notice, the Multiple Myeloma Research Foundation and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.

  • Bispecific Antibody Therapy in Multiple Myeloma related image

    Concensus Recommendations for Management of Infections in Patients Receiving Bispecific Antibody Therapy

    Show more
  • Bispecific Antibody Discussion Handout image

    Bispecific Antibody Discussion Handout

    Show more
  • Terminology Criteria for Adverse Events image

    Common Terminology Criteria for Adverse Events (CTCAE)

    Show more
Recommended
Details
Presenters
Related
Comments

  • Overview

    Release date: 7/18/2024
    Expiration date: 7/18/2025
    Estimated time to complete: 1.0 hour

    This activity is not accredited for CME/CE credit.

    This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.

  • Provider(s)/Educational Partner(s)

    Jointly provided by:

  • Commercial Support

    Support for this activity has been provided through educational grants from Johnson & Johnson and Pfizer, Inc.

  • Target Audience

    This activity has been designed to meet the educational needs of community hematologist-oncologists and other health care providers involved in the care of RRMM patients.

  • Learning Objectives

    After completing this activity, participants should be better able to:

    • Evaluate recent clinical advances in the use of bispecific antibody therapy in patients with RRMM and their implications for clinical practice
    • Summarize the toxicity profiles of bispecific antibodies used in the treatment of RRMM, particularly with respect to CRS, neurotoxicity, and infections
    • Employ the recommended strategies to monitor for treatment complications and manage AEs associated with bispecific antibody therapy

  • Unapproved Product Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, and Pfizer do not recommend the use of any agent outside the labeled indications.

  • Disclaimer

    The information presented in this activity is for medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, or Pfizer. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Contact Information

  • Privacy

    This content is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. The information you provide on this site may be used to contact you about other relevant educational activities. RedMedEd will not knowingly share any personally identifiable information. For more information, contact education@redmeded.com.

  • Copyright

    © 2024. This program is held as copyrighted by the Multiple Myeloma Research Foundation and RedMedEd. Through this notice, the Multiple Myeloma Research Foundation and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.

  • Bispecific Antibody Therapy in Multiple Myeloma related image

    Concensus Recommendations for Management of Infections in Patients Receiving Bispecific Antibody Therapy

    Show more
  • Bispecific Antibody Discussion Handout image

    Bispecific Antibody Discussion Handout

    Show more
  • Terminology Criteria for Adverse Events image

    Common Terminology Criteria for Adverse Events (CTCAE)

    Show more
Schedule31 Aug 2024
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended